- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Terig Hughes
Group Chief Financial Officer
Terig is the Group Chief Financial Officer of Volition having joined the company in February 2021.
Terig is the Group Chief Financial Officer of Volition having joined the company in February 2021. He is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience, including product commercialization, licensing and distributor management, gained through an international career spanning US, Europe and Asia.
Prior to joining Volition, Terig was the CFO at AUM Biosciences, a fast-growing biotechnology company focused on developing novel cancer drugs having previously held a number of senior leadership positions at Elsevier, a division of RELX plc, a FTSE 100 company, including regional Managing Director and regional Finance Director for Elsevier Health Solutions.
Terig received a Bachelor’s degree in Accounting and Law from De Montfort University, Leicester, UK.
“I find Volition’s proposition very appealing. Not only will Nu.Q® product launches help save lives through earlier diagnosis, but they also have the potential to generate good returns for our investors.”
Terig Hughes
Group Chief Financial Officer